Human herpes virus 8 in solid organ transplantation

Transplantation

Volumn 92, Issue 8, 2011, Pages 837-844

  Ariza Heredia, Ella J ^a   Razonable, Raymund R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Herpes; Lymphoma; Sarcoma

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CIDOFOVIR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAUNORUBICIN; ETOPOSIDE; FOSCARNET; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; LYMPHOCYTE ANTIBODY; NUCLEIC ACID; PREDNISONE; RAPAMYCIN; RITUXIMAB; VALGANCICLOVIR; VINCRISTINE;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ASYMPTOMATIC DISEASE; CANCER CHEMOTHERAPY; CANCER SUSCEPTIBILITY; CLINICAL FEATURE; DIAGNOSTIC TEST; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; ENDEMIC DISEASE; GEOGRAPHIC DISTRIBUTION; GRAFT RECIPIENT; HEART TRANSPLANTATION; HERPES VIRUS INFECTION; HIGH RISK POPULATION; HUMAN; HUMAN HERPESVIRUS 8; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KAPOSI SARCOMA; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; NUCLEIC ACID ANALYSIS; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEROLOGY; SEROPREVALENCE; VIRUS CELL INTERACTION; VIRUS LATENCY; VIRUS REACTIVATION; VIRUS TRANSMISSION;

GIANT LYMPH NODE HYPERPLASIA; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 8, HUMAN; HUMANS; LYMPHOMA, PRIMARY EFFUSION; ORGAN TRANSPLANTATION; RISK FACTORS; SARCOMA, KAPOSI;

EID: 80054773903     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31823104ec     Document Type: Review

References (62)

1. Edelman DC. Human herpesvirus 8-A novel human pathogen. Virol J 2005; 2: 78.
2. Pica F, Volpi A. Transmission of human herpesvirus 8: An update. Curr Opin Infect Dis 2007; 20: 152.
3. Al-Otaibi LM, Al-Sulaiman MH, Teo CG, et al. Extensive oral shedding of human herpesvirus 8 in a renal allograft recipient. Oral Microbiol Immunol 2009; 24: 109.
4. Hladik W, Dollard SC, Mermin J, et al. Transmission of human herpesvirus 8 by blood transfusion. N Engl J Med 2006; 355: 1331.
5. Regamey N, Tamm M, Wernli M, et al. Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients. N Engl J Med 1998; 339: 1358.
6. Luppi M, Barozzi P, Schulz TF, et al. Bone marrow failure associated with human herpesvirus 8 infection after transplantation.NEngl J Med 2000; 343: 1378.
7. Coleman CB, Nealy MS, Tibbetts SA. Immature and transitional B cells are latency reservoirs for a gammaherpesvirus. J Virol 2010; 84: 13045.
8. Ganem D. KSHV and the pathogenesis of Kaposi sarcoma: Listening to human biology and medicine. J Clin Invest 2010; 120: 939.
9. Wen KW, Damania B. Kaposi sarcoma-associated herpesvirus (KSHV): Molecular biology and oncogenesis. Cancer Lett 2010; 289: 140.
10. Cannon G. Out of the box. Public Health Nutr 2003; 6: 427.
11. Moore PS, Chang Y. Molecular virology of Kaposi's sarcoma-associated herpesvirus. Philos Trans R Soc Lond B Biol Sci 2001; 356: 499.
12. Lennette ET, Blackbourn DJ, Levy JA. Antibodies to human herpesvirus type 8 in the general population and in Kaposi's sarcoma patients. Lancet 1996; 348: 858.
13. Qu L, Jenkins F, Triulzi DJ. Human herpesvirus 8 genomes and seroprevalence in United States blood donors. Transfusion 2010; 50: 1050.
14. Jenkins FJ, Hoffman LJ, Liegey-Dougall A. Reactivation of and primary infection with human herpesvirus 8 among solid-organ transplant recipients. J Infect Dis 2002; 185: 1238.
15. García-Astudillo LA, Leyva-Cobián F. Human herpesvirus-8 infection and Kaposi's sarcoma after liver and kidney transplantation in different geographical areas of Spain. Transpl Immunol 2006; 17: 65.
16. Bergallo M, Costa C, Margio S, et al. Human herpes virus 8 infection in kidney transplant patients from an area of northwestern Italy (Piemonte region). Nephrol Dial Transplant 2007; 22: 1757.
17. Gao SJ, Kingsley L, Li M, et al. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med 1996; 2: 925.
18. Sabeel AI, Qunibi WY, Alfurayh OA, et al. Kaposi's sarcoma in Sudanese renal transplant recipients: A report from a single center. J Nephrol 2003; 16: 412.
19. Einollahi B, Lessan-Pezeshki M, Nourbala MH, et al. Kaposi's sarcoma following living donor kidney transplantation: Review of 7,939 recipients. Int Urol Nephrol 2009; 41: 679.
20. Mohanna S, Maco V, Bravo F, et al. Epidemiology and clinical characteristics of classic Kaposi's sarcoma, seroprevalence, and variants of human herpesvirus 8 in South America: A critical review of an old disease. Int J Infect Dis 2005; 9: 239.
21. Mbulaiteye SM, Engels EA. Kaposi's sarcoma risk among transplant recipients in the United States (1993-2003). Int J Cancer 2006; 119: 2685.
22. Luppi M, Barozzi P, Santagostino G, et al. Molecular evidence of organrelated transmission of Kaposi sarcoma-associated herpesvirus or human herpesvirus-8 in transplant patients. Blood 2000; 96: 3279.
23. Huang JY, Chiang YJ, Lai PC, et al. Posttransplant Kaposi's sarcoma: Report from a single center. Transplant Proc 2004; 36: 2145.
24. Serrano CV Jr., Nicolau JC, Venturinelli M, et al. Role of oral blockade of platelet glycoprotein IIb/IIIa on neutrophil activation in patients with acute coronary syndromes. Cardiovasc Drugs Ther 2003; 17: 129.
25. Lebb éC, Legendre C, Francés C. Kaposi sarcoma in transplantation. Transplant Rev 2008; 22: 252.
26. Moosa MR. Kaposi's sarcoma in kidney transplant recipients: A 23- year experience. QJM 2005; 98: 205.
27. Al-Khader AA, Suleiman M, Al-Hasani M, et al. Posttransplant Kaposi sarcoma: Staging as a guide to therapy and prognosis. Nephron 1988; 48: 165.
28. Aoki Y, Tosato G. Pathogenesis and manifestations of human herpesvirus- 8-associated disorders. Semin Hematol 2003;40(2):143-153. (Pubitemid 36461092)
29. Ohori NP, Whisnant RE, Nalesnik MA, Swerdlow SH. Primary pleural effusion posttransplant lymphoproliferative disorder: Distinction from secondary involvement and effusion lymphoma. Diagn Cytopathol 2001;25(1):50-53. (Pubitemid 32622641)
30. Jones D, Ballestas ME, Kaye KM, et al. Primary-effusion lymphoma and Kaposi's sarcoma in a cardiac-transplant recipient. N Engl J Med 1998; 339: 444.
31. Wang HY, Fuda FS, Chen W, et al. Notch1 in primary effusion lymphoma: A clinicopathological study. Mod Pathol 2010; 23: 773.
32. Dotti G, Fiocchi R, Motta T, et al. Primary effusion lymphoma after heart transplantation: A new entity associated with human herpesvirus-8. Leukemia 1999; 13: 664.
33. Melo NC, Sales MM, Santana AN, et al. Pleural primary effusion lymphoma in a renal transplant recipient. Am J Transplant 2008; 8: 906.
34. Boulanger E, Afonso PV, Yahiaoui Y, et al. Human herpesvirus-8 (HHV- 8)-associated primary effusion lymphoma in two renal transplant recipients receiving rapamycin. Am J Transplant 2008; 8: 707.
35. Thaunat O, Mamzer-Bruneel MF, Agbalika F, et al. Severe human herpesvirus-8 primary infection in a renal transplant patient successfully treated with anti-CD20 monoclonal antibody. Blood 2006; 107: 3009.
36. Lim EJ, Crowley P, Mitchell CA, et al. Post-liver transplantation multicentric Castleman disease treated with valganciclovir and weaning of immunosuppression. Am J Transplant 2011; 11: 169.
37. Gaitonde S, Vidanovic V, Ni H. Concomitant and fatal HHV-8multicentric Castleman's disease and Kaposi's sarcoma in the same lymph node of an HIV-liver transplant patient. Histopathology 2007; 50: 954.
38. Al Otaibi T, Al Sagheir A, Ludwin D, et al. Post renal transplant Castleman's disease resolved after graft nephrectomy: A case report. Transplant Proc 2007; 39: 1276.
39. Kapelushnik J, Ariad S, Benharroch D, et al. Post renal transplantation human herpesvirus 8-associated lymphoproliferative disorder and Kaposi's sarcoma. Br J Haematol 2001; 113: 425.
40. Régnier-Rosencher E, Barrou B, Marcelin AG, et al. [Primary effusion lymphoma in two kidney transplant recipients]. Ann Dermatol Venereol 2010; 137: 285.
41. Luppi M, Barozzi P, Schulz TF, et al. Bone marrow failure associated with human herpesvirus 8 infection after transplantation.NEngl J Med 2000; 343: 1378.
42. Luppi M, Barozzi P, Rasini V, et al. Severe pancytopenia and hemophagocytosis after HHV-8 primary infection in a renal transplant patient successfully treated with foscarnet. Transplantation 2002; 74: 131.
43. Tedeschi R, Kvarnung M, Knekt P, et al. A prospective seroepidemiological study of human herpesvirus-8 infection and the risk of multiple myeloma. Cr J Cancer 2001;84(1):122-125. (Pubitemid 32102517)
44. Lyons SF, Liebowitz DN. The roles of human viruses in the pathogenesis of lymphoma. Semin Oncol 1998;25(4):461-475. (Pubitemid 28385723)
45. Razonable RR, Zerr DM. HHV-6, HHV-7 and HHV-8 in solid organ transplant recipients. Am J Transplant 2009; 9(suppl 4): S100.
46. Corchero JL, Mar EC, Spira TJ, et al. Comparison of serologic assays for detection of antibodies against human herpesvirus 8. Clinical Diagn Lab Immunol 2001; 8: 913.
47. Campbell TB, Borok M, Gwanzura L, et al. Relationship of human herpesvirus 8 peripheral blood virus load and Kaposi's sarcoma clinical stage. AIDS 2000; 14: 2109.
48. Tedeschi R, Marus A, Bidoli E, Simonelli C, De Paoli P. Human herpesvirus 8 DNA quantification in matched plasma and PBMC samples of patients with HHV-8 related lymphoproliferative diseases. J Clin Virol 2008;43(3):255-259.
49. Tedeschi R, Enbom M, Bidoli E, et al. Viral load of human herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with Kaposi's sarcoma. J Clin Microbiol 2001; 39: 4269.
50. Pellet C, Chevret S, Frances C, et al. Prognostic value of quantitative Kaposi sarcoma-associated herpesvirus load in posttransplantation Kaposi sarcoma. J Infect Dis 2002; 186: 110.
51. Singh N. Infections with human herpesvirus 6-7, and 8 after hematopoietic stem cell transplant or solid organ transplant. In: Bowden RA, Ljungman P, Snydman DR, eds. Transplant infections. Philadelphia, PA, Lippincott Williams & Wilkins 2010, pp 411.
52. Shepherd FA, Maher E, Cardella C, et al. Treatment of Kaposi's sarcoma after solid organ transplantation. J Clin Oncol 1997; 15: 2371.
53. Barozzi P, Bonini C, Potenza L, et al. Changes in the immune responses against human herpesvirus-8 in the disease course of posttransplant Kaposi sarcoma. Transplantation 2008; 86: 738.
54. Stallone G, Infante B, Grandaliano G, et al. Kaposi's sarcoma and mTOR: A crossroad between viral infection neoangiogenesis and immunosuppression. Transpl Int 2008; 21: 825.
55. Monaco AP. The role of mTOR inhibitors in the management of posttransplant malignancy. Transplantation 2009; 87: 157.
56. Patel N, Salifu M, Sumrani N, et al. Successful treatment of postrenal transplant Kaposi's sarcoma with paclitaxel. Am J Transplant 2002; 2: 877.
57. Brambilla L, Romanelli A, Bellinvia M, et al. Weekly paclitaxel for advanced aggressive classic Kaposi sarcoma: Experience in 17 cases. Br J Dermatol 2008; 158: 1339.
58. Martin DF, Kuppermann BD, Wolitz RA, et al. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med 1999; 340: 1063.
59. Casper C, Krantz EM, Corey L, et al. Valganciclovir for suppression of human herpesvirus-8 replication: A randomized, double-blind, placebocontrolled, crossover trial. J Infect Dis 2008; 198: 23.
60. Francés C, Marcelin AG, Legendre Ch, et al. The impact of preexisting or acquired Kaposi sarcoma herpesvirus infection in kidney transplant recipients on morbidity and survival. Am J Transplant 2009; 9: 2580.
61. Allen UD. Human herpesvirus type 8 infections among solid organ transplant recipients. Pediatr Transplant 2002; 6: 187.
62. Dupin N, Marcelin AG, Gorin I, et al. Prevalence of human herpesvirus 8 infection measured by antibodies to a latent nuclear antigen in patients with various dermatologic diseases. Arch Dermatol 1998; 134: 700.